Patent ID: 11919870
Assignee: JANSSEN PHARMACEUTICA NV
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC C

Claim 0:
1. A method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I):, , wherein
X is CH2 or O;
R1 is H;
R2a and R2b are each independently selected from H and C1-4alkyl;
R3 is selected from:
(i) phenyl, benzyl, or monocyclic heteroaryl, each optionally substituted with one, two, or three substituents selected from: halo, C1-6alkyl, C1-6haloalkyl, C1-6alkyl-OH, OC1-6alkyl, OC1-6haloalkyl, SC1-6alkyl, SF5, Si(CH3)3, NRaRb, C3-6cycloalkyl, OC3-6cycloalkyl, phenyl, O-phenyl, and O-pyridyl, wherein each cycloalkyl, phenyl, or pyridyl is optionally substituted with one or two C1-4alkyl, C1-4haloalkyl, or halo groups; or two adjacent ring substituents on the phenyl, benzyl, or monocyclic heteroaryl, taken together with the atoms to which they are attached form a fused monocyclic C5-6 cycloalkyl or heterocycloalkyl ring, each ring optionally substituted with one or two C1-4alkyl, C1-4haloalkyl, or halo groups;
wherein Ra and Rb are each independently H or C1-4alkyl;
(ii) a bicyclic heteroaryl optionally substituted with C1-4alkyl or halo; and
(iii) C3-6 alkyl or C3-6 cycloalkyl optionally substituted with C1-4alkyl, C1-4haloalkyl, or halo;
R4 is C1-6alkyl;

or a pharmaceutically acceptable salt, isotope, N-oxide, solvate, or stereoisomer thereof;
wherein the disease, disorder, or condition mediated by MGL receptor activity is selected from the group consisting of major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder;
and wherein treating comprises ameliorating the disease, disorder, or condition mediated by MGL receptor activity.